

Freedom of Information Request Ref: UHB 19-626

18 October 2019

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

Request:

- 1. How many patients have you treated for complicated skin and soft tissue infections (cSSTI) in the last 12 months with the following:
 - Ceftaroline (Zinforo)
 - Flucloxacillin
 - Meropenem (Meronem)
 - Teicoplanin (Targocid)
 - Tigecycline
 - Vancomycin
- 2. How many patients have you treated for community acquired pneumonia in the last 12 months with the following:
 - Ceftaroline (Zinforo)
 - Ceftriaxone
 - Ceftobiprole (Zevtera)
 - Co-Amoxiclav
 - Isavuconazole (Cresemba)
 - Meropenem (Meronem)
- 3. How many patients have you treated mucormycosis with the following in the last 12 months
 - Amphotericin B/amphotericin liposomal (AmBisome)
 - Isavuconazole (Cresemba)
 - Posaconazole (Noxafil)
- 4. How many patients with Gram negative infections, have you treated in the lst 12 months with:
 - Amoxicillin/clauvanate

- Piperacillin/tazobactam
- Ceftazidime/avibactam
- Ceftolozane/tazobactam
- Carbapenems (e.g. Ertapenem, Imipenem, Meropenem etc)
- Aminoglycosides (e.g. Gentamicin, Amikacin, Tobramycin)
- Cephalosporins (e.g. Cefotaxime, Ceftazidime, Ceftriaxone)
- Quinolones (e.g.Ciprofloxacin, Levofloxacin, Ofloxacin)

Response:

The Trust can report on how many patients were admitted/treated for each of the indications stated but not the drug(s) they were treated with.

That would require manual trawl of patient notes to interrogate the data on a drug to disease specification.

This would take the Trust more than 18 hours to complete and is therefore exempt from disclosure under Section 12 of the Freedom of Information Act.

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance University Hospitals Bristol NHS Foundation Trust Trust Headquarters Marlborough Street Bristol BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

<u>Publication</u>

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information

(such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click here.

Yours sincerely

FOI Team UH Bristol NHS Foundation Trust